Patent US4742003A successfully refreshed from Google Patents.
US4742003A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human transforming growth factor
Assignee: Genentech Inc
•
Filing: 1985-05-14
•
Granted: 1988-05-03
•
Expires: 2005-05-14
Abstract
Abstract Methods and compositions are provided for the recombinant synthesis of the tumor growth factor-α precursor and its fragments. These are useful in therapy and diagnosis, as are antibodies raised by immunization with the tumor growth factor-α precursor and its fragment.
Inventors
- 👤 Rik M. A. Derynck
- 👤 David V. Goeddel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:18
CPC Classifications
A; A61; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K16/00; C07K16/18; C07K16/22; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/57575; G01N33/5758; G01N33/57585; G01N33/74; A61K; A61K38/00; G01N2333/00; G01N2333/435; G01N2333/475; G01N2333/495; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/828; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
81 words
An expression vector comprising a DNA sequence encoding a human TGF-α species selected from the group of (1) precursor TGF-α; (2) a biologically active fragment of precursor TGF-α having at least about 50 residues; or (3) a biologically active mutant of precursor TGF-α or a fragment of precursor TGF-α having at least about 50 residues, wherein an amino acid residue has been inserted, substituted or deleted in or from the amino acid sequence of the precursor TGF-α sequence or its fragment.
Claim 2
Dependent Claim
81 words
An expression vector comprising a DNA sequence encoding a human TGF-α species selected from the group of (1) precursor TGF-α; (2) a biologically active fragment of precursor TGF-α having at least about 50 residues; or (3) a biologically active mutant of precursor TGF-α or a fragment of precursor TGF-α having at least about 50 residues, wherein an amino acid residue has been inserted, substituted or deleted in or from the amino acid sequence of the precursor TGF-α sequence or its fragment.
Claim 3
Dependent Claim
28 words
The vector of claim 1 wherein the biologically active mutant binds to a cell surface receptor for TGF-α and is an insertional or substitutional mutant of mature TGF-α.
Claim 4
Dependent Claim
11 words
The vector of claim 2 wherein the fragment is mature TGF-α.
Claim 5
Dependent Claim
23 words
The vector of claim 1 wherein the mutant comprises an insertion of a heterologous polypeptide at carboxyl-terminus and/or amino terminus of mature TGF-α.
Claim 6
Dependent Claim
19 words
The vector of claim 3 wherein a methionyl residue is added to the amino terminus of the mature TGF-α.
Claim 7
Dependent Claim
11 words
The vector of claim 1 which is a plasmid or virus.
Claim 8
Independent Claim
130 words
A method for producing a TGF-α species, comprising (a) preparing an expression vector comprising a DNA sequence encoding a human precursor TGF-α species selected from the group of (1) precursor TGF-α; (2) a biologically active fragment of precursor TGF-α having at least about 50 residues; or (3) a biologically active mutant of precursor TGF-α, or a fragment thereof having at least about 50 residues, wherein an amino acid residue has been inserted, substituted or deleted in or from the amino acid sequence of the precursor TGF-α sequence or its fragment; (b) transforming said host cell with the expression vector to obtain a recombinant host cell; (c) culturing the recombinant host cell under conditions for expression of the TGF-α species; and (d) recovering the TGF-α species from the host cell culture.
Claim 9
Independent Claim
130 words
A method for producing a TGF-α species, comprising (a) preparing an expression vector comprising a DNA sequence encoding a human precursor TGF-α species selected from the group of (1) precursor TGF-α; (2) a biologically active fragment of precursor TGF-α having at least about 50 residues; or (3) a biologically active mutant of precursor TGF-α, or a fragment thereof having at least about 50 residues, wherein an amino acid residue has been inserted, substituted or deleted in or from the amino acid sequence of the precursor TGF-α sequence or its fragment; (b) transforming said host cell with the expression vector to obtain a recombinant host cell; (c) culturing the recombinant host cell under conditions for expression of the TGF-α species; and (d) recovering the TGF-α species from the host cell culture.
Claim 10
Dependent Claim
11 words
The method of claim 7 wherein the host cell is yeast.
Claim 11
Dependent Claim
12 words
The method of claim 7 wherein the TGF-α species is mature TGF-α.
Claim 12
Dependent Claim
18 words
The method of claim 7 wherein the TGF-α species is recovered as insoluble aggregates and thereafter is resolubilized.
Claim 13
Dependent Claim
24 words
The method of claim 7 wherein the TGF-α species is secreted from the host cells and is recovered from the host cell culture medium.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-05-03 | 1991-11-02 | 1992-05-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-05-03 | 1995-11-02 | 1996-05-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-05-03 | 1999-11-02 | 2000-05-03 | $7700.00 | Window Closed / Lapsed |